The pharmaceutical industry faces a perfect storm, with unsustainable growth in healthcare costs, increasing costs of drug discovery, and the shift to a value-based payment model.
The benefits of adherent patients are no secret: better outcomes, a more stable treatment pathway and of course better revenues for pharma are all possible.
Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas